Trends and Outcome from Radical Therapy for Primary Non-Metastatic Prostate Cancer in a UK Population

Radical Therapy

Primary Radical Therapy Selection in High-risk Non-metastatic Prostate Cancer

Clinical Oncology ◽

10.1016/j.clon.2014.11.004 ◽

2015 ◽

Vol 27 (3) ◽

pp. 136-144 ◽

Cited By ~ 9

Author(s):

V.J. Gnanapragasam ◽

H. Payne ◽

I. Syndikus ◽

H. Kynaston ◽

T. Johnstone

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Primary Radical ◽

Radical Therapy

1197: Prognostic Value of Hemoglobin Change after Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis of Swog 8894

10.1016/s0022-5347(18)33422-0 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 385-386

Author(s):

Tomasz M. Beer ◽

Bryan H. Goldman ◽

Catherine M. Tangen ◽

Lisa B. Bland ◽

Maha Hussain ◽

...

Keyword(s):

Prostate Cancer ◽

Multivariate Analysis ◽

Prognostic Value ◽

Newly Diagnosed

646: 25-Year Outcomes of Radical Prostatectomy for the Treatment of All Stages of Non-Metastatic Prostate Cancer

10.1016/s0022-5347(18)32892-1 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 208-208

Author(s):

Brant A. Inman ◽

Jeffrey M. Slezak ◽

Eugene D. Kwon ◽

Robert P. Myers ◽

Bradley C. Leibovich ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

1181: Bicalutamide 150 MG in Addition to Standard Care in Patients With Early, Non-Metastatic Prostate Cancer: Results from the SPCG-6 Study at a Median Follow-up of 5.3 Years

10.1016/s0022-5347(18)38418-0 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 311-312 ◽

Cited By ~ 3

Author(s):

Peter Iversen

Keyword(s):

Prostate Cancer ◽

Standard Care ◽

1062: Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Years' follow-up

10.1016/s0022-5347(18)38299-5 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 280-281 ◽

Cited By ~ 2

Author(s):

William A. See ◽

Peter Iversen ◽

David G. McLeod ◽

Manfred P. Wirth ◽

Kevin Carroll ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Standard Care ◽

Specific Antigen ◽

Progression Free Survival ◽

Free Survival

158: The Impact of Skeletal-Related Events on Preferences and Health-Related Quality of Life of Patients with Metastatic Prostate Cancer

10.1016/s0022-5347(18)37420-2 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 42-42 ◽

Cited By ~ 1

Author(s):

Kevin P. Weinfurt ◽

Liana D. Castel ◽

Yun Li ◽

Fred Saad ◽

Justin W. Timbie ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Health Related Quality ◽

Related Quality ◽

Health Related ◽

Skeletal Related Events ◽

The Impact

Abstract #624: Severe Refractory Hypocalcemia Following Administration of Denosumab in Metastatic Prostate Cancer

Endocrine Practice ◽

10.1016/s1530-891x(20)45101-8 ◽

2016 ◽

Vol 22 ◽

pp. 140

Author(s):

Natalia Chaar Tirado ◽

Sandeep Dhindsa

Keyword(s):

Prostate Cancer ◽

The role of WNT5A in tumor and tumor surrounding tissue in primary and metastatic prostate cancer

10.1055/s-0040-1717547 ◽

2020 ◽

Author(s):

W Kisel ◽

S Conrad ◽

S Füssel ◽

U Sommer ◽

GB Baretton ◽

...

Keyword(s):

Prostate Cancer ◽

Surrounding Tissue

Severe hypocalcemia after a single denosumab injection and tumor-induced persistent hypophosphatemia in a patient with metastatic prostate cancer

Endocrine Abstracts ◽

10.1530/endoabs.64.039 ◽

2019 ◽

Author(s):

Theunissen Aude ◽

Roumeguere Thierry ◽

Corvilain Bernard ◽

Kyrilli Aglaia

Keyword(s):

Prostate Cancer ◽

Docetaxel-Loaded Liquid Crystalline Nanoparticles Wrapped with Graphene Oxide for Effective Chemo-Photothermal Therapy of Metastatic Prostate Cancer Cells

10.26226/morressier.57d6b2b6d462b8028d88d525 ◽

2016 ◽

Author(s):

Raj Thapa

Keyword(s):

Prostate Cancer ◽

Graphene Oxide ◽

Cancer Cells ◽

Photothermal Therapy ◽

Liquid Crystalline ◽

Prostate Cancer Cells ◽

Liquid Crystalline Nanoparticles